Difference between revisions of "Renal cell carcinoma, VHL-associated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "|Phase II" to "|Phase 2")
m
Line 1: Line 1:
−
{| class="wikitable" style="text-align:center; width:50%;"
+
{{#lst:Section editor transclusions|gu}}
−
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
 
−
|-
 
−
| style="background-color:#F0F0F0" |[[File:Alikhaki.jpg|frameless|upright=0.3|center]]
 
−
|<big>[[User:Alikhaki|Ali Raza Khaki, MD]]<br>Stanford University<br>Palo Alto, CA</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/arkhaki arkhaki]
 
−
|-
 
−
|}
 
 
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the '''[[Renal cell carcinoma|main RCC page]]''' for other regimens.
 
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the '''[[Renal cell carcinoma|main RCC page]]''' for other regimens.
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"

Revision as of 23:55, 8 May 2022

Section editor transclusions Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page
1 variants on this page


All lines of therapy

Belzutifan monotherapy

back to top

Regimen

Study Years of enrollment Evidence
Jonasch et al. 2021 (MK-6482-004) 2018-2019 Phase 2 (RT)

Targeted therapy

Continued indefinitely

References

  1. MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains verified protocol Pubmed NCT03401788
Retrieved from "https://hemonc.org/w/index.php?title=Renal_cell_carcinoma,_VHL-associated&oldid=56271"